Warning: Fluoroquinolones Double Risk of Aortic Aneurysm


Researchers have determined that use of fluoroquinolones could double your risk of suffering an aortic aneurysm.  Aortic aneurysm is a potentially life-threatening condition that may be caused by the side effects of fluoroquinolone antibiotics.  Aortic dissection risks are also increased with use of these medications. Continue reading “Warning: Fluoroquinolones Double Risk of Aortic Aneurysm”

Some Antibiotics Now Labeled with Stronger Warnings Following FDA Decision

The U.S. Food and Drug Administration recently required a new warning for peripheral neuropathy and tendon injuries on a group of antibiotics called fluoroquinolones. Drugs in this class include:  Levaquin (levofloxacin); Cipro (ciprofloxacin); Avelos (moxifloxacin); and Floxin (ofloxacin) Factive (gemifloxacin). Continue reading “Some Antibiotics Now Labeled with Stronger Warnings Following FDA Decision”

Heartburn Medications Nexium, Prilosec, and Prevacid Linked to Kidney Disease


Common over-the-counter (OTC) heartburn medications like Prilosec, Prevacid, and Nexium are linked to increasing the risk of chronic kidney disease. These drugs are known as proton pump inhibitors (PPI). The OTC heartburn medicine is used to tame heartburn and reduce acid reflux. Continue reading “Heartburn Medications Nexium, Prilosec, and Prevacid Linked to Kidney Disease”

Six Gilead Sciences Trials Halted Following Deaths Involving Idelalisib (Zydelig) Drug

Gilead Sciences has immediately halted the continuation of six clinical trials. The US Food and Drug Administration (FDA) says that the use of Idelaslisib (Zydelig) has led to serious adverse events and several deaths in clinical trial participants. Continue reading “Six Gilead Sciences Trials Halted Following Deaths Involving Idelalisib (Zydelig) Drug”

Benicar Warning: Medication Causes Dangerous and Undisclosed Side Effects

Benicar, also known as olmesartan, has been linked to dangerous side effects in patients nationwide. The drug is manufactured by Daiichi Sankyo and Forest Laboratories. Daiichi Sankyo is based in Japan. The serious side effects were experienced  while maintaining proper dosages of the drug. Continue reading “Benicar Warning: Medication Causes Dangerous and Undisclosed Side Effects”

MS Drug Laquinimod Linked to 8 Non-Fatal Cardiovascular Events

Following findings that eight patients experienced significant, non-life threatening heart incidents, Teva Pharmaceutical Industries Ltd. And Active Biotech AB have ceased phase-2 and phase-3 clinical trial studies of Laquinimod.  Laquinimod is used for the treatment of multiple sclerosis and Huntington Disease. The U.S. Food and Drug Administration (FDA) requires phase 3 clinical trial completion before a drug can obtain approval for distribution on a large scale. Continue reading “MS Drug Laquinimod Linked to 8 Non-Fatal Cardiovascular Events”

Chantix (varenicline): FDA Issues Drug Safety Communication Regarding Update to Label

On March 9, 2015, the FDA updated the safety label for Chantix to include how the drug (1) could change the way users react to alcohol and (2) be associated with seizures.

Chantix (varenicline) is an FDA-approved prescription drug manufactured by Pfizer, used to help adults quit smoking.  Chantix works by reducing cravings for and decreasing the pleasurable effects of cigarettes and other tobacco products. Continue reading “Chantix (varenicline): FDA Issues Drug Safety Communication Regarding Update to Label”

Tecfidera Label Change and FDA Drug Safety Communication Regarding PML

The U.S. Food and Drug Administration (FDA) recently announced that it added new information to the label for Tecfidera (dimethyl fumarate) regarding progressive multifocal leukoencephalopathy (PML). The FDA based its decision on a report of a multiple sclerosis (MS) patient who, while being treated with Tecfidera, developed PML then died.

The patient was a 54 year-old woman with MS. She had been using it for four and a half years and was not taking other drugs that affected her immune system. She had no medical conditions that would predispose her to PML. Continue reading “Tecfidera Label Change and FDA Drug Safety Communication Regarding PML”